Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.

“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”

“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

SUFFOLK, Va. and MOORESVILLE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Mooresville based blueharbor bank (OTCQX: BLHK) (“blueharbor”), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire blueharbor for approximately $154 million, based on TowneBank’s 10-day volume-weighted average price of $36.15 as of October 2, 2026. The proposed transaction will enhance TowneBank’s position in the greater Charlotte MSA as well as the fast-growing I-77 corridor including Mooresville and Statesville. The combination brings together blueharbor’s strong local lending and core deposit relationships with TowneBank’s broader resources, creating a stronger platform to serve customers across the region. The transaction is expected to further leverage TowneBank’s recent expansion throughout the Carolina markets.

As of June 30, 2026, blueharbor had total assets of approximately $628 million, loans of approximately $537 million, deposits of approximately $551 million, and 5 office locations.

“We are excited to welcome blueharbor and its talented team to the TowneBank family,” said G. Robert Aston, Jr., Executive Chairman of TowneBank. “blueharbor has a long history of stellar performance along with an excellent reputation across the communities it serves. This partnership reflects TowneBank’s ongoing efforts to attract experienced banking talent and build meaningful growth markets.”

“blueharbor was built on a focus upon customers, businesses and communities throughout the I-77 corridor,” said Jim Marshall, President and Chief Executive Officer of blueharbor. “We are excited to partner with TowneBank, whose commitment to community banking and serving others closely reflects our own. Our customers will benefit from TowneBank’s broader range of products, services and technology while continuing to receive the local service they value.”

“I have known Jim Marshall for years, and we are extremely proud to have him and his team as members of our TowneBank family,” said Steve Jones, President, TowneBank of the Carolinas.

Under the terms of the agreement, shareholders of blueharbor will receive $12.70 in cash and 1.0534 shares of TowneBank common stock for each share of blueharbor outstanding common stock, for an implied value of $50.78 per share based on TowneBank’s 10-day volume-weighted average price. The total consideration mix results in approximately 75% of the transaction paid in TowneBank common stock.

Following the consummation of the merger, Kelley Earnhardt Miller, Chairman of the blueharbor Board of Directors and Chief Executive Officer of JR Motorsports, will join the TowneBank family as a member of the TowneBank Corporate Board of Directors, and Jim Marshall will join the TowneBank family as Piedmont Regional President.

The definitive agreement was approved by the boards of directors of TowneBank and blueharbor. The transaction is expected to close in the first quarter of 2027 and is subject to customary closing conditions, including regulatory approval, as well as the approval of blueharbor’s shareholders.

Piper Sandler & Co. served as the financial advisor and Wachtell, Lipton, Rosen & Katz and Williams Mullen served as legal counsel to TowneBank in the transaction. D.A. Davidson & Co. served as financial advisor and Brooks, Pierce, McLendon, Humphrey & Leonard, LLP served as legal counsel to blueharbor in the transaction.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.6 billion as of June 30, 2026, TowneBank is one of the largest banks headquartered in Virginia.

About blueharbor:
blueharbor bank is a community bank headquartered in Mooresville, North Carolina, with approximately $628 million in total assets as of June 30, 2026. Founded in 2008, blueharbor provides personal and business banking products and services through branch offices in Mooresville, Statesville and Mount Airy, as well as loan production offices in Belmont and Hickory. The bank serves customers throughout the region with a focus on long-standing relationships and local decision-making.

Media Contact:
G. Robert Aston, Jr., Executive Chairman of TowneBank, 757-638-6780
William I. Foster III, President and Chief Executive Officer of TowneBank, 757-417-6482
Jim Marshall, President and Chief Executive Officer of blueharbor bank, 704-662-7700

Investor Contact:
William B. Littreal, Chief Financial Officer of TowneBank, 757-638-6813

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of TowneBank and blueharbor and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of TowneBank and blueharbor. Forward-looking statements may be identified by the use of such words as: “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional terms, such as “will,” “would,” “should,” “could,” “may,” “likely,” “probably,” or “possibly.” These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including statements about (i) the benefits of the transaction, including future financial and operating results, cost savings, enhancement to revenue and accretion to reported earnings that may be realized from the transaction and (ii) TowneBank’s and blueharbor’s plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although TowneBank’s and blueharbor’s respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements because of possible uncertainties.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of blueharbor may not be successfully integrated into TowneBank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction); (5) the outcome of any legal proceedings that may be instituted against TowneBank or blueharbor; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between TowneBank and blueharbor; (7) reputational risk and potential adverse reactions of TowneBank’s or blueharbor’s customers, employees or other business partners, including those resulting from the announcement or completion of the transaction; (8) the dilution caused by TowneBank’s issuance of additional shares of its capital stock in connection with the transaction; (9) the diversion of management’s attention and time from ongoing business operations and opportunities on merger-related matters; (10) economic, legislative or regulatory changes, including changes in accounting standards and changes impacting the rulemaking, supervision, examination and enforcement priorities of the federal banking agencies, that may adversely affect the businesses in which TowneBank and blueharbor are engaged; (11) competitive pressures in the banking industry that may increase significantly; (12) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (13) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize TowneBank’s or blueharbor’s overall liquidity or capitalization; (14) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (15) insufficiency of TowneBank’s or blueharbor’s allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (16) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (17) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (18) geopolitical instability, including wars, conflicts, trade restrictions and tariffs, civil unrest, and terrorist attacks and the potential impact, directly or indirectly, on TowneBank’s or blueharbor’s business; (19) the effects of weather-related or natural disasters, which may negatively affect TowneBank’s or blueharbor’s operations and/or TowneBank’s or blueharbor’s loan portfolio and increase the cost of conducting business; (20) public health events (such as the COVID-19 pandemic) and governmental and societal responses to them; (21) the introduction of new lines of business or new products and services; (22) cybersecurity threats or attacks, whether directed at TowneBank or blueharbor or at vendors or other third parties with which TowneBank or blueharbor interact; (23) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (24) changes in business conditions; (25) changes in the securities market; and (26) changes in the local economies with regard to TowneBank’s and blueharbor’s respective market areas.

Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in TowneBank’s reports filed with the Federal Deposit Insurance Corporation (“FDIC”). TowneBank and blueharbor undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information and Where to Find It

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of TowneBank or a solicitation of any vote or approval. blueharbor will deliver a definitive proxy statement/offering circular to its shareholders seeking approval of the merger and related matters. In addition, TowneBank may file other relevant documents concerning the proposed merger with the FDIC. Before making any voting or investment decision, investors and security holders are urged to read the proxy statement/offering circular and any other relevant documents to be filed with the FDIC in connection with the proposed transaction because they contain important information about TowneBank, blueharbor, and the proposed merger.

Shareholders are also urged to carefully review TowneBank’s public filings with the FDIC, including, but not limited to, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements. Free copies of filings containing information about TowneBank may be obtained after their filing at the FDIC’s website (https://www.fdic.gov). The documents described above also may be obtained by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23435, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.” In addition, free copies of the definitive proxy statement/offering circular, when available, may be obtained by directing a request by telephone or mail to blueharbor bank, P.O. Box 3546, 106 Corporate Park Dr., Mooresville, North Carolina 28117, Attention: Jim Marshall (telephone: (704) 662-7700) or by accessing blueharbor’s website at https://www.blueharborbank.com under “Newsroom.” The information on TowneBank’s website and blueharbor’s website is not, and shall not be deemed to be, a part of this press release or incorporated into other filings TowneBank makes with the FDIC.

Participants in the Solicitation

TowneBank, blueharbor, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of blueharbor in connection with the proposed merger. Information about the directors and executive officers of blueharbor and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the proxy statement/offering circular when it becomes available. Additional information about the directors and executive officers of TowneBank can be found in TowneBank’s proxy statement in connection with its annual meeting of shareholders, filed with the FDIC on April 10, 2026. Additional information about the directors and executive officers of blueharbor can be found in blueharbor’s proxy statement in connection with its annual meeting of shareholders, as sent previously to blueharbor’s shareholders on or about April 6, 2026.

  • Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027.
  • Multiple scaled-up batches of CXU™ material met predefined specifications, supporting both regulatory testing and future commercial production.

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today provided an update on the regulatory and manufacturing program supporting its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten Minute Tissue™, its lead wound care device candidate, as well as on the Company’s broader preparations for commercialization.

The Company is conducting manufacturing, testing, and preclinical work intended to support its planned FDA 510(k) submission. Conexeu remains on track to make the submission in the first calendar quarter of 2027.

The Company views manufacturing scale-up as a key stage in the transition of Ten Minute Tissue™ from a development-stage product candidate toward a potential commercial product. Establishing a controlled and reproducible manufacturing process is expected to support not only the generation of representative materials for regulatory testing, but also the development of supply capabilities intended to meet future market demand subject to FDA clearance.

Recent manufacturing activities represent an important step forward in the program. Following process-development work, multiple scaled-up batches of CXU™ material met predefined Company specifications for key material characteristics and product performance measures.

“We have moved from process development to implementing a controlled manufacturing process,” said Miles Harrison, President and CEO of Conexeu. “That progress is important for two reasons. First, it supports the regulatory testing required to advance our planned FDA 510(k) submission. Second, it moves us closer to establishing the scalable manufacturing infrastructure needed to support commercialization. We believe manufacturing scale-up is one of the critical bridges between regulatory development and our ability to ultimately bring our lead device to market.”

Advancing the Ten Minute Tissue™ Regulatory and Manufacturing Program

Conexeu’s current regulatory and development activities include:

  • Manufacturing process development and scale-up. Recent activities have demonstrated reproducible performance of CXU™ material across multiple scaled-up batches.
  • Regulatory test-material production. The Company is expanding production of representative Ten Minute Tissue™ test samples, made to reflect the final product, to support planned preclinical, biocompatibility, chemical characterization, stability and other regulatory testing.
  • Progress toward commercial manufacturing readiness. Conexeu is evaluating and developing manufacturing processes, supplier relationships and production capabilities intended to support the transition from development-scale production to larger-volume, controlled manufacturing subject to regulatory clearance.
  • Preclinical wound evaluation. Conexeu is advancing its preclinical (non-human) wound model study program, including pilot studies, intended to generate data supporting substantial equivalence to an identified predicate device (a comparable device already legally sold in the U.S.).
  • Biocompatibility and product characterization. Workstreams include biocompatibility (how the material interacts with tissues), chemical characterization (a detailed analysis of the material’s chemical makeup), product performance and other testing expected to support the Company’s FDA 510(k) submission.
  • Sterilization, packaging and stability. The Company continues work on sterilization, packaging integrity and the product container systems, as well as stability testing (how the product holds up in storage over time), in parallel with preclinical work.
  • FDA engagement. Conexeu has received feedback from the FDA through the agency’s Q-Submission process and is incorporating that advisory feedback into its ongoing development and regulatory planning.

“Wherever appropriate, we are running these workstreams at the same time rather than one after another, using representative test materials made with our controlled manufacturing process,” said Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu. “This approach keeps our planned first-quarter 2027 submission on track while maintaining the consistency that regulatory testing requires.”

About Ten Minute Tissue™

Ten Minute Tissue™ is built on the Company’s CXU™ platform, which is based on the extracellular matrix (ECM), the natural framework that holds the body’s tissues together. Conexeu plans to focus its commercial strategy on wound care, where it believes two features of Ten Minute Tissue™ set it apart: it can be applied as a liquid, and it is designed to turn into a gel at body temperature within about ten minutes, the feature that gives the device candidate its name [1] [7] [9]. Many difficult wounds are irregularly shaped. Examples include deep tissue openings left after skin cancer removal (known as Mohs surgery), surgical wounds that have split back open, burns, and wounds that form channels beneath the skin. Because Ten Minute Tissue™ is designed to flow into place and then set, it is intended to fill gaps and channels that sheets, meshes, and powders may not fully reach, and to stay in close contact with the entire wound surface. Once set, it is designed to act as a framework, or “scaffold,” that the body’s own cells can move into, intended to support natural tissue repair [3] [5] [6] [7] [9] [10].

About the FDA 510(k) Pathway

Conexeu intends to seek FDA clearance for Ten Minute Tissue™ in wound care through the 510(k) premarket notification pathway. Under a 510(k), a company submits evidence that its device is substantially equivalent to a device already legally marketed in the U.S., meaning it has the same intended use and is at least as safe and effective. The FDA’s performance goal is to reach a decision within 90 days of active FDA review, a clock that pauses while the company responds to any FDA questions. The 510(k) pathway is generally shorter than the FDA’s premarket approval (PMA) process for higher-risk devices, which typically relies on clinical trials that can take years to complete.

About Conexeu Sciences Inc.

Architecting Bioregeneration™. Conexeu Sciences is a preclinical-stage medical device and regenerative medicine company. Our patented extracellular matrix (ECM) platform, CXU™, is built on a single structural principle and is designed to support bioregeneration: one formula, one device, designed to scale across multiple addressable markets.

Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

About CXU™

CXU™ is designed to support soft tissue lost through injury, aging, and the tissue changes that can follow GLP-1 weight loss. The Company’s lead device candidate, Ten Minute Tissue™, is a thermosensitive extracellular matrix (ECM) that remains fluid at room temperature and is designed to transition to a stable gel in situ at body temperature within approximately ten minutes. In preclinical research, Ten Minute Tissue™ has been characterized for host cell infiltration, vascular ingrowth, organized remodeling, and a low-inflammatory profile, conditions intended to support constructive remodeling. [1]

The platform is grounded in more than a decade of university preclinical research and protected by a multi-jurisdictional patent estate spanning more than 40 jurisdictions (U.S., EU, Japan, and Australia, with protection pending in Canada). Conexeu owns the platform IP, holding all rights, title, and interest, with no royalty or licensing obligations, and intends to expand across new indications and markets.

Sources

[1] Hartwell R., Leung V., Chavez-Munoz C., et al. A novel hydrogel-collagen composite improves functionality of an injectable extracellular matrix. Acta Biomaterialia (2011); 7; 3060-3069. [2] Hosseini-Tabatabaei A., Jalili R., Hartwell R., et al. Embedding islet in a liquid scaffold increases islet viability and function. Canadian Journal of Diabetes (2013); 37; 27-35 [3] Hartwell R., Poormasjedi-Meibod M.S., Chavez-Munoz C., et al. An in-situ forming skin substitute improves healing outcome in a hypertrophic scar model. Tissue Engineering Part A (2015); 21(5); 1085-1094. [4] Hosseini-Tabatabaei A., Jalili R., Khosravi-Maharlooei M., et al. Immunoprotection and functional improvement of allogeneic islets in diabetic mice, using stable indoleamine 2,3-dioxygenase producing scaffold. Transplantation (2015); 99; 1342-1348. [5] Hartwell R., Chan B., Elliott K., et al. Polyvinyl alcohol-graft-polyethylene glycol hydrogels improve utility and biofunctionality of injectable collagen biomaterials. Biomedical Materials (2016); 11; 035013. [6] Forbes D., Russ B., Kilani R.T., et al. Liquid dermal scaffold with adipose-derived stem cells improves tissue quality in a murine model of impaired wound healing. Journal of Burn Care & Research (2019); 40(5); 550-557. [7] Pourghadiri A., Alnojeidi H., Jalili R., et al. In situ forming nutritional and temperature sensitive scaffold improves the aesthetic outcome of meshed split-thickness skin grafts in a porcine model. Advances in Wound Care (2021); 10(3); 113-122. [8] Pangli H., Vatanpour S., Hortamani S., et al. Incorporation of silver nanoparticles in hydrogel matrices for controlling wound infection. Journal of Burn Care & Research (2021); 42(4); 785-793. [9] Pakyari M., Jalili R., Kilani R.T., et al. Studying the in vivo application of a liquid dermal scaffold in promoting wound healing. Experimental Dermatology (2021); 31; 715-724. [10] Alnojeidi H., Kilani R.T., Ghahary A. Evaluating the biocompatibility of an injectable wound matrix in a murine model. Gels (2022); 8, 49.

All cited studies [1]–[10]   are preclinical. Preclinical results are not necessarily predictive of clinical outcomes. Ten Minute Tissue™ is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. None of the cited studies evaluated CXU™ specifically in the wound care indications described (post-Mohs defects, dehiscent, burn, or tunneling wounds); these wound care applications represent the design-intent application of the underlying CXU™ platform, and supporting evidence in indication-specific preclinical models is being developed by the Company.

Trademarks. CXU™, Ten Minute Tissue™, and Architecting Bioregeneration™ are trademarks of Conexeu Sciences Inc.

Investor and Media Contacts:

Gateway Group
CNXU@Gateway-grp.com
949.574.3860

astr partners
josh.barer@astrpartners.com
(908) 578-6478

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States securities laws. These statements relate to analysis and other information that are based on forecasts or future results, estimates of amounts not yet determinable, and assumptions of management, including, but not limited to, statements regarding regulatory pathway, submission timing, category development and platform expansion. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. We have based these forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Our actual future results may differ materially from those discussed or implied in our forward-looking statements for various reasons. Factors that could contribute to such differences include, but are not limited to: international, national and local general economic and market conditions; demographic changes; the early-stage, preclinical nature of the Company’s device candidates, including B.R.E.A.S.T.™ and Ten Minute Tissue™, and the inherent uncertainty of preclinical and clinical development, including the possibility that preclinical results may not be predictive of clinical outcomes; preclinical study objectives described as met may not result in clinical benefit, regulatory clearance, or commercial success; the investigational status of CXU™, which is not cleared or approved for marketing in any jurisdiction, and that no assurance can be given that any such clearance or approval will be obtained; risks associated with the Company’s planned 510(k) submission, including the possibility that the submission may not be completed within the anticipated first-quarter 2027 timeframe or at all; the risk that the FDA may not accept the 510(k) submission as filed, may request additional information, data, or testing, or may determine that the device is not substantially equivalent to the identified predicate device; the risk that marketing clearance for the CXU™ wound-care device may not be obtained, may be delayed, or may be subject to conditions or limitations that affect the Company’s commercial plans; changes in FDA regulatory policy, guidance, or review standards applicable to 510(k) submissions or the Company’s identified predicate devices; the ability of the Company to sustain, manage or forecast its growth; the ability of the company to develop and commercialize its products; the ability of the Company to raise capital to complete its plans and fund its operations; the commercial viability of the contemplated processing plant; the continued availability of key leadership personnel; adverse publicity; competition and changes in the advanced wound care market, medical aesthetics market and tissue engineering and reconstruction; fluctuations and difficulty in forecasting operating results; business disruptions, such as technological failures and/or cybersecurity breaches. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release. The forward-looking statements included in this release are made only as of the date hereof. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This news release shall not constitute an offer to sell or the solicitation of any offer to buy our securities.

  • Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027.
  • Multiple scaled-up batches of CXU™ material met predefined specifications, supporting both regulatory testing and future commercial production.

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today provided an update on the regulatory and manufacturing program supporting its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten Minute Tissue™, its lead wound care device candidate, as well as on the Company’s broader preparations for commercialization.

The Company is conducting manufacturing, testing, and preclinical work intended to support its planned FDA 510(k) submission. Conexeu remains on track to make the submission in the first calendar quarter of 2027.

The Company views manufacturing scale-up as a key stage in the transition of Ten Minute Tissue™ from a development-stage product candidate toward a potential commercial product. Establishing a controlled and reproducible manufacturing process is expected to support not only the generation of representative materials for regulatory testing, but also the development of supply capabilities intended to meet future market demand subject to FDA clearance.

Recent manufacturing activities represent an important step forward in the program. Following process-development work, multiple scaled-up batches of CXU™ material met predefined Company specifications for key material characteristics and product performance measures.

“We have moved from process development to implementing a controlled manufacturing process,” said Miles Harrison, President and CEO of Conexeu. “That progress is important for two reasons. First, it supports the regulatory testing required to advance our planned FDA 510(k) submission. Second, it moves us closer to establishing the scalable manufacturing infrastructure needed to support commercialization. We believe manufacturing scale-up is one of the critical bridges between regulatory development and our ability to ultimately bring our lead device to market.”

Advancing the Ten Minute Tissue™ Regulatory and Manufacturing Program

Conexeu’s current regulatory and development activities include:

  • Manufacturing process development and scale-up. Recent activities have demonstrated reproducible performance of CXU™ material across multiple scaled-up batches.
  • Regulatory test-material production. The Company is expanding production of representative Ten Minute Tissue™ test samples, made to reflect the final product, to support planned preclinical, biocompatibility, chemical characterization, stability and other regulatory testing.
  • Progress toward commercial manufacturing readiness. Conexeu is evaluating and developing manufacturing processes, supplier relationships and production capabilities intended to support the transition from development-scale production to larger-volume, controlled manufacturing subject to regulatory clearance.
  • Preclinical wound evaluation. Conexeu is advancing its preclinical (non-human) wound model study program, including pilot studies, intended to generate data supporting substantial equivalence to an identified predicate device (a comparable device already legally sold in the U.S.).
  • Biocompatibility and product characterization. Workstreams include biocompatibility (how the material interacts with tissues), chemical characterization (a detailed analysis of the material’s chemical makeup), product performance and other testing expected to support the Company’s FDA 510(k) submission.
  • Sterilization, packaging and stability. The Company continues work on sterilization, packaging integrity and the product container systems, as well as stability testing (how the product holds up in storage over time), in parallel with preclinical work.
  • FDA engagement. Conexeu has received feedback from the FDA through the agency’s Q-Submission process and is incorporating that advisory feedback into its ongoing development and regulatory planning.

“Wherever appropriate, we are running these workstreams at the same time rather than one after another, using representative test materials made with our controlled manufacturing process,” said Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu. “This approach keeps our planned first-quarter 2027 submission on track while maintaining the consistency that regulatory testing requires.”

About Ten Minute Tissue™

Ten Minute Tissue™ is built on the Company’s CXU™ platform, which is based on the extracellular matrix (ECM), the natural framework that holds the body’s tissues together. Conexeu plans to focus its commercial strategy on wound care, where it believes two features of Ten Minute Tissue™ set it apart: it can be applied as a liquid, and it is designed to turn into a gel at body temperature within about ten minutes, the feature that gives the device candidate its name [1] [7] [9]. Many difficult wounds are irregularly shaped. Examples include deep tissue openings left after skin cancer removal (known as Mohs surgery), surgical wounds that have split back open, burns, and wounds that form channels beneath the skin. Because Ten Minute Tissue™ is designed to flow into place and then set, it is intended to fill gaps and channels that sheets, meshes, and powders may not fully reach, and to stay in close contact with the entire wound surface. Once set, it is designed to act as a framework, or “scaffold,” that the body’s own cells can move into, intended to support natural tissue repair [3] [5] [6] [7] [9] [10].

About the FDA 510(k) Pathway

Conexeu intends to seek FDA clearance for Ten Minute Tissue™ in wound care through the 510(k) premarket notification pathway. Under a 510(k), a company submits evidence that its device is substantially equivalent to a device already legally marketed in the U.S., meaning it has the same intended use and is at least as safe and effective. The FDA’s performance goal is to reach a decision within 90 days of active FDA review, a clock that pauses while the company responds to any FDA questions. The 510(k) pathway is generally shorter than the FDA’s premarket approval (PMA) process for higher-risk devices, which typically relies on clinical trials that can take years to complete.

About Conexeu Sciences Inc.

Architecting Bioregeneration™. Conexeu Sciences is a preclinical-stage medical device and regenerative medicine company. Our patented extracellular matrix (ECM) platform, CXU™, is built on a single structural principle and is designed to support bioregeneration: one formula, one device, designed to scale across multiple addressable markets.

Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

About CXU™

CXU™ is designed to support soft tissue lost through injury, aging, and the tissue changes that can follow GLP-1 weight loss. The Company’s lead device candidate, Ten Minute Tissue™, is a thermosensitive extracellular matrix (ECM) that remains fluid at room temperature and is designed to transition to a stable gel in situ at body temperature within approximately ten minutes. In preclinical research, Ten Minute Tissue™ has been characterized for host cell infiltration, vascular ingrowth, organized remodeling, and a low-inflammatory profile, conditions intended to support constructive remodeling. [1]

The platform is grounded in more than a decade of university preclinical research and protected by a multi-jurisdictional patent estate spanning more than 40 jurisdictions (U.S., EU, Japan, and Australia, with protection pending in Canada). Conexeu owns the platform IP, holding all rights, title, and interest, with no royalty or licensing obligations, and intends to expand across new indications and markets.

Sources

[1] Hartwell R., Leung V., Chavez-Munoz C., et al. A novel hydrogel-collagen composite improves functionality of an injectable extracellular matrix. Acta Biomaterialia (2011); 7; 3060-3069. [2] Hosseini-Tabatabaei A., Jalili R., Hartwell R., et al. Embedding islet in a liquid scaffold increases islet viability and function. Canadian Journal of Diabetes (2013); 37; 27-35 [3] Hartwell R., Poormasjedi-Meibod M.S., Chavez-Munoz C., et al. An in-situ forming skin substitute improves healing outcome in a hypertrophic scar model. Tissue Engineering Part A (2015); 21(5); 1085-1094. [4] Hosseini-Tabatabaei A., Jalili R., Khosravi-Maharlooei M., et al. Immunoprotection and functional improvement of allogeneic islets in diabetic mice, using stable indoleamine 2,3-dioxygenase producing scaffold. Transplantation (2015); 99; 1342-1348. [5] Hartwell R., Chan B., Elliott K., et al. Polyvinyl alcohol-graft-polyethylene glycol hydrogels improve utility and biofunctionality of injectable collagen biomaterials. Biomedical Materials (2016); 11; 035013. [6] Forbes D., Russ B., Kilani R.T., et al. Liquid dermal scaffold with adipose-derived stem cells improves tissue quality in a murine model of impaired wound healing. Journal of Burn Care & Research (2019); 40(5); 550-557. [7] Pourghadiri A., Alnojeidi H., Jalili R., et al. In situ forming nutritional and temperature sensitive scaffold improves the aesthetic outcome of meshed split-thickness skin grafts in a porcine model. Advances in Wound Care (2021); 10(3); 113-122. [8] Pangli H., Vatanpour S., Hortamani S., et al. Incorporation of silver nanoparticles in hydrogel matrices for controlling wound infection. Journal of Burn Care & Research (2021); 42(4); 785-793. [9] Pakyari M., Jalili R., Kilani R.T., et al. Studying the in vivo application of a liquid dermal scaffold in promoting wound healing. Experimental Dermatology (2021); 31; 715-724. [10] Alnojeidi H., Kilani R.T., Ghahary A. Evaluating the biocompatibility of an injectable wound matrix in a murine model. Gels (2022); 8, 49.

All cited studies [1]–[10]   are preclinical. Preclinical results are not necessarily predictive of clinical outcomes. Ten Minute Tissue™ is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. None of the cited studies evaluated CXU™ specifically in the wound care indications described (post-Mohs defects, dehiscent, burn, or tunneling wounds); these wound care applications represent the design-intent application of the underlying CXU™ platform, and supporting evidence in indication-specific preclinical models is being developed by the Company.

Trademarks. CXU™, Ten Minute Tissue™, and Architecting Bioregeneration™ are trademarks of Conexeu Sciences Inc.

Investor and Media Contacts:

Gateway Group
CNXU@Gateway-grp.com
949.574.3860

astr partners
josh.barer@astrpartners.com
(908) 578-6478

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States securities laws. These statements relate to analysis and other information that are based on forecasts or future results, estimates of amounts not yet determinable, and assumptions of management, including, but not limited to, statements regarding regulatory pathway, submission timing, category development and platform expansion. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. We have based these forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Our actual future results may differ materially from those discussed or implied in our forward-looking statements for various reasons. Factors that could contribute to such differences include, but are not limited to: international, national and local general economic and market conditions; demographic changes; the early-stage, preclinical nature of the Company’s device candidates, including B.R.E.A.S.T.™ and Ten Minute Tissue™, and the inherent uncertainty of preclinical and clinical development, including the possibility that preclinical results may not be predictive of clinical outcomes; preclinical study objectives described as met may not result in clinical benefit, regulatory clearance, or commercial success; the investigational status of CXU™, which is not cleared or approved for marketing in any jurisdiction, and that no assurance can be given that any such clearance or approval will be obtained; risks associated with the Company’s planned 510(k) submission, including the possibility that the submission may not be completed within the anticipated first-quarter 2027 timeframe or at all; the risk that the FDA may not accept the 510(k) submission as filed, may request additional information, data, or testing, or may determine that the device is not substantially equivalent to the identified predicate device; the risk that marketing clearance for the CXU™ wound-care device may not be obtained, may be delayed, or may be subject to conditions or limitations that affect the Company’s commercial plans; changes in FDA regulatory policy, guidance, or review standards applicable to 510(k) submissions or the Company’s identified predicate devices; the ability of the Company to sustain, manage or forecast its growth; the ability of the company to develop and commercialize its products; the ability of the Company to raise capital to complete its plans and fund its operations; the commercial viability of the contemplated processing plant; the continued availability of key leadership personnel; adverse publicity; competition and changes in the advanced wound care market, medical aesthetics market and tissue engineering and reconstruction; fluctuations and difficulty in forecasting operating results; business disruptions, such as technological failures and/or cybersecurity breaches. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release. The forward-looking statements included in this release are made only as of the date hereof. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This news release shall not constitute an offer to sell or the solicitation of any offer to buy our securities.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.